BioMonitor 2 In-Office Setting Insertion Safety and Feasibility Evaluation With Device Functionality Assessment

Inclusion Criteria: * Indicated for continuous monitoring with an insertable cardiac monitor * Willing to be implanted in an office setting with only local anesthetic available * Able to understand the nature of the study and provide informed consent * Able and willing to complete all routine follow-up visits at the study site for the expected 90-day follow-up * Able and willing to use a CardioMessenger® capable of communicating with the BioMonitor 2 * Age greater than or equal to 18 years At the time of insertion, the following pre-procedure criteria must be met for the subject to undergo insertion: * Most recent INR value (within 7 days) is less than 3.5 if currently taking warfarin * Absence of infection with no history of infection within the last 30 days Exclusion Criteria: * Compromised immune system or at high risk of developing an infection * Abnormal thoracic anatomy or scar tissue at the implant site that may adversely impact the insertion procedure * Enrolled in any investigational cardiac device trial * Currently indicated for or implanted with a pacemaker, ICD device, or hemodynamic monitoring system * Currently implanted with an ICM or ILR * Life expectancy less than 6 months * Patients reporting pregnancy at the time of enrollment